Please Wait.....
Report
Astellas Pharma Inc. (4503:TYO) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI's, and Recent Trends
Company Report I 2024-11-22 I 88 Pages I Quaintel Research
Report Summary
Year End Offer - Buy Now and get an updated version of this Report at no extra cost within 30 days of the release of Company's next Annual Report. (Offer expires on 31st Dec 2024)
Astellas Pharma Inc. (4503:TYO) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI's, and Recent Trends Report is a comprehensive and easily accessible overview of Astellas Pharma Inc.'s business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about Astellas Pharma Inc. including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses Astellas Pharma Inc.'s strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Astellas Pharma Inc.'s overall strategic standing and supports informed decision-making and strategic planning.
The report also covers Astellas Pharma Inc.'s financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Astellas Pharma Inc.'s financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.
Finally, the report includes recent news and deal activities undertaken by Astellas Pharma Inc. enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
Astellas Pharma Inc. operates as a pharmaceutical company that manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. Astellas Pharma Inc. operates in the pharmaceuticals segment providing treatments for diseases like cancer, anemia, overactive bladder and also offers immunosuppressants.
Astellas Pharma Inc. offers pharmaceutical products and services including XTANDI for prostate cancer, XOSPATA for acute myeloid leukemia, PADCEV for urothelial cancer, Evrenzo for anemia, Betanis/Myrabetriq/BETMIGA for overactive bladder, and Prograf and Advagraf/Graceptor/ASTAGRAF XL as immunosuppressants. The company provides treatments for various diseases and conditions. Founded in 1923, the company is headquartered in Tokyo, Japan.
Astellas Pharma Inc. in the News:-
- 28-Oct-2024 - Astellas Provides Update on Marketing Authorization Application for Avacincaptad Pegol (ACP) in the European Union
- 25-Oct-2024 - Every Day of Vision Loss Is One Too Many: Addressing the Impact of Eye Diseases
- 21-Oct-2024 - stellas' VYLOYTM (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
- 18-Oct-2024 - Silence, Stigma, and Misunderstanding: Our Mission to Break Down Barriers in Menopause
- 10-Oct-2024 - Astellas to Present VEOZATM (fezolinetant) Data at IMS World Congress on Menopause
Scope
- Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
- Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
- Comprehensive Understanding of the Astellas Pharma Inc.'s internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.
- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company Astellas Pharma Inc.:
- Astellas Pharma Inc. Value Chain Analysis
- Astellas Pharma Inc. Porter's Five Forces Analysis
- Astellas Pharma Inc. VRIO Analysis
- Astellas Pharma Inc. BCG Analysis
- Astellas Pharma Inc. Segmentation, Targeting and Positioning (STP) Analysis
- Astellas Pharma Inc. Ansoff Matrix Analysis
Table of Contents
COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 6
Charts 7
Astellas Pharma Inc.-Key Company Facts 8
Astellas Pharma Inc.- Company Description 9
Astellas Pharma Inc.- Top Executives 10
Astellas Pharma Inc.- Head Office & Locations 12
Head Office - Country 12
Astellas Pharma Inc.- Productsand Services 13
Products 13
Services 14
Astellas Pharma Inc.- Corporate Strategy 15
Astellas Pharma Inc.- Business Description 18
Immunology Segment 19
Urology Segment 20
Oncology Segment 20
Astellas Pharma Inc.- ESG Spotlight 21
Environment 22
Social 22
Corporate Governance 22
Astellas Pharma Inc.- SWOT Analysis 24
Overview 24
Strengths 26
Weaknesses 30
Opportunities 31
Threats 33
Astellas Pharma Inc.- PESTLE Analysis 34
Overview 34
Political Factors 36
Economic Factors 38
Social Factors 39
Technological Factors 41
Legal Factors 43
Environmental Factors 44
Astellas Pharma Inc.- Financial Deep Dive 45
Share Price Trend - Nov-2023 to Nov-2024 (Average Share Closing Price) 45
Profit and Loss Statement 47
Summary of Profit and Loss Statement 47
Balance Sheet 49
Summary of Balance Sheet 49
Cash Flow Statement 51
Summary of Cash Flow Statement 51
Key Financial Ratio Analysis 53
Astellas Pharma Inc.- Ratio Charts 54
Activity Ratio Charts 54
Growth Ratios Charts 55
Leverage Ratio Charts 56
Liquidity Ratio Charts 57
Profitability Ratio Charts 58
Competing Players 59
Snapshot of Competing Players 60
Johnson & Johnson 60
Key Company Facts 60
Company Description 60
Novartis AG 61
Key Company Facts 61
Company Description 61
Pfizer Inc. 62
Key Company Facts 62
Company Description 62
Merck & Co., Inc. 63
Key Company Facts 63
Company Description 63
GlaxoSmithKline Pharmaceuticals Ltd 64
Key Company Facts 64
Company Description 64
Astellas Pharma Inc. - In the News 65
28-Oct-2024 -Astellas Provides Update on Marketing Authorization Application for Avacincaptad Pegol (ACP) in the European Union 65
25-Oct-2024 -Every Day of Vision Loss Is One Too Many: Addressing the Impact of Eye Diseases 66
21-Oct-2024 -stellas' VYLOYTM (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer 66
18-Oct-2024 -Silence, Stigma, and Misunderstanding: Our Mission to Break Down Barriers in Menopause 68
10-Oct-2024 -Astellas to Present VEOZATM (fezolinetant) Data at IMS World Congress on Menopause 70
08-Oct-2024 -Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications 71
30-Sep-2024 -Notice Regarding Foreign Exchange Loss 72
24-Sep-2024 -Japan's Ministry of Health, Labour and Welfare Approves PADCEVTM (enfortumab vedotin) with KEYTRUDA (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma 72
30-May-2024 -U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE 74
21-May-2024 -Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies 76
19-May-2024 -Patient Centricity and AI: Navigating the Promise and Pitfalls 77
15-May-2024 -Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme 80
Appendix 81
Definitions 81
SWOT Analysis 81
PESTLE Analysis 81
Value Chain Analysis 81
ESG Spotlight 81
Financial Deep Dive 81
Financial Ratios- 82
Activity Ratios 82
Growth Ratios 83
Leverage Ratios 84
Liquidity Ratios 85
Market Ratios 86
Profitability Ratios 86
Research Methodology 87
Disclaimer 88
Contact Us 88
Tables
Table 1: Astellas Pharma Inc. - Company Facts
Table 2: Astellas Pharma Inc. - Digital Presence
Table 3: Astellas Pharma Inc.- Top Executives
Table 4: Astellas Pharma Inc.- Products
Table 5: Astellas Pharma Inc.-Services
Table 6: Astellas Pharma Inc. - Share Price Trend - Nov-2023to Nov-2024
Table 7: Astellas Pharma Inc. - Ratio Analysis -2021-2024
Table 8: Astellas Pharma Inc. - Competing Players
Table 9: Competing Players - Johnson & Johnson - Key Company Facts
Table 10: Competing Players - Novartis AG - Key Company Facts
Table 11: Competing Players - Pfizer Inc. - Key Company Facts
Table 12: Competing Players - Merck & Co., Inc. - Key Company Facts
Table 13: Competing Players - GlaxoSmithKline Pharmaceuticals Ltd - Key Company Facts
Charts
Figure 1: Astellas Pharma Inc.- SWOT Analysis 25
Figure 2: Astellas Pharma Inc.-PESTLE Analysis 35
Figure 3: Astellas Pharma Inc.-Average Share Price Trend - Nov-2023to Nov-2024 46
Figure 4: Astellas Pharma Inc.- Profit and Loss Statement -2021-2024 48
Figure 5: Astellas Pharma Inc.- Balance Sheet-2021-2024 50
Figure 6: Astellas Pharma Inc.- Cash Flow Statement 2021-2024 52
Figure 7: Astellas Pharma Inc.- Activity Ratio Charts 54
Figure 8: Astellas Pharma Inc.- Growth Ratio Charts (Value %) 55
Figure 9: Astellas Pharma Inc.- Leverage Ratio Charts 56
Figure 10: Astellas Pharma Inc.- Liquidity Ratio Charts 57
Figure 11: Astellas Pharma Inc.- Profitability Ratio Charts (Value %) 58
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security